March 8, 2022
Just the facts
There has been a great deal of noise surrounding the insulin space, so we thought we’d bring those pesky facts into the arena. Here are the numbers from the three largest insulin companies for 2021
Lilly
Humalog $2453 Billion
Humulin $1222.6 Billion
Basaglar $892.5 Million
Novo Nordisk
Long Acting $2648.37 Billion
Pre-Mix $1642.48 Billion
Fast Acting $2593.10 Billion
Sanofi
Lantus $2721.45 Billion
Toujeo $1057.37 Billion
Add it all . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
